课题基金 / 基金详情

Improving Minority Health in Rheumatic Diseases

Improving Minority Health in Rheumatic Diseases
改善少数民族风湿病健康
批准号:
9902868
负责人:
Gary S Gilkeson
金额:
$55.05万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-25 至 2022-08-31

项目摘要

项目成果

Gary S Gilkeson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT Systemic Lupus Erythematosus is a significant chronic disease with morbidity and mortality in primarily young women of color. Our current P30 CCCR grant “Improving Minority Health in Rheumatic Diseases” is composed of three cores, administrative, methodology and patient resource. These cores provide the infrastructure for studies directed at understanding the pathogenesis of lupus and scleroderma as a method to achieve better diagnostics and treatments for these diseases. In this Administrative Supplement to the P30 we are proposing two specific projects focused on decreasing ethnic disparities in lupus to be performed at MUSC and the University of Alabama at Birmingham. The first project is to provide awareness, education and early screening in young African American females through programs and efforts at Historically Black Colleges and Universities in South Carolina and Alabama. The second project is to utilize a patient advocate for high risk African American female lupus patients based on missed appointments, medication non adherence and ER visits at both institutions. The advocate will work with the patients to improve these parameters believing that such navigation in lupus will be as successful as similar efforts in HIV. We also propose an enhancement effort consisting of a pilot project each year for both institutions, a mentoring program for junior investigators in health disparities and cross institutional sharing of expertise. The CCCR program does not include projects, but only cores. We propose to utilize this supplement mechanism to pursue projects we believe will have direct impact on ethnic disparities in lupus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
Improving Minority Health in Rheumatic Diseases
Improving Minority Health in Rheumatic Diseases
海外基金